Review

Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

In-Sung Song, Hyoung-Kyu Kim, Seung-Hun Jeong, Sung-Ryul Lee, Nari Kim, Byoung Doo Rhee, Kyung Soo Ko and Jin Han *

National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 614-7-5, Korea; E-Mails: microvirus@hanmail.net (I.-S.S.); estrus74@gmail.com (H.-K.K.); shjeong96@gmail.com(S.-H.J.); lsr1113@hotmail.com(S.-R.L.); narikim43@gmail.com(N.K.); bdrhee@hanmail.net (B.D.R.); kskomd@paik.ac.kr (K.S.K.)

* Author to whom correspondence should be addressed; E-Mail: phyhanj@inje.ac.kr; Tel.: +82-51-890-6727; Fax: +82-51-894-5714.

Received: 29 July 2011; in revised form: 30 September 2011 / Accepted: 20 October 2011 / Published: 21 October 2011

Abstract: Mitochondria are involved either directly or indirectly in oncogenesis and the alteration of metabolism in cancer cells. Cancer cells contain large numbers of abnormal mitochondria and produce large amounts of reactive oxygen species (ROS). Oxidative stress is caused by an imbalance between the production of ROS and the antioxidant capacity of the cell. Several cancer therapies, such as chemotherapeutic drugs and radiation, disrupt mitochondrial homeostasis and release cytochrome c, leading to apoptosome formation, which activates the intrinsic pathway. This is modulated by the extent of mitochondrial oxidative stress. The peroxiredoxin (Prx) system is a cellular defense system against oxidative stress, and mitochondria in cancer cells are known to contain high levels of Prx III. Here, we review accumulating evidence suggesting that mitochondrial oxidative stress is involved in cancer, and discuss the role of the mitochondrial Prx III antioxidant system as a potential target for cancer therapy. We hope that this review will provide the basis for new strategic approaches in the development of effective cancer treatments.
Keywords: ROS; mitochondria; peroxiredoxin III; cancer; antioxidant; oxidative stress; therapy

1. Mitochondria and Cancer

As the main energy producers in cells, mitochondria subject substrates to oxidative phosphorylation, thereby generating the energy molecule ATP. During this process, mitochondria inevitably generate reactive oxygen species (ROS). ROS are involved in the regulation of many physiological processes, including cell signaling, but are harmful to cells if produced in excessive amounts. Furthermore, mitochondria, which are crucial regulators of the intrinsic pathway of apoptosis, perform vital and lethal functions in physiological and pathological contexts [1,2]. Mitochondria control the activation of apoptotic effector mechanisms by regulating the translocation of pro-apoptotic proteins from the mitochondrial intermembrane space to the cytosol. In addition, they play a major role in multiple forms of non-apoptotic cell death [3]. In this context, mitochondrial abnormalities occur in various diseases, including cardiovascular, neurodegenerative, metabolic diseases, and cancer.

In cancer cells, key mitochondrial regulators of cell death and other processes are often altered [4]. Cancer-cell mitochondria differ structurally and functionally from their normal-cell counterparts [4,5]. Rapidly growing tumors readily become hypoxic due to the inability of the local vasculature to supply an adequate amount of oxygen. Furthermore, mutations in mitochondrial and nuclear DNA that affect components of the mitochondrial respiratory chain result in inefficient ATP production, ROS overproduction, and oxidative damage to mitochondria and macromolecules [5]. Over 70 years ago, Warburg pioneered research into alterations in mitochondrial respiration in the context of cancer and proposed a mechanism to explain how they evolve during the carcinogenic process [6]. This process differs from that in normal cells, which utilize oxidative phosphorylation primarily for growth and survival. Although the observation of high rates of aerobic glycolysis in tumor cells has been corroborated, the role of mitochondria in tumor cells has been contentious [7]. The major role of aerobic glycolysis in cancer cells is likely to be the generation of glycolytic intermediates for the pentose phosphate pathway in nucleotide and phospholipid synthesis, while glycolytic ATP generation is likely to be important for survival under hypoxic conditions [8]. The glutamine-fueled TCA cycle generates ATP, ROS, nicotinamide adenine dinucleotide phosphate (NADPH), amino acids, and lipids. The synthesis of ATP requires large amounts of oxygen, which routinely leads to the generation of ROS such as hydrogen peroxide, the superoxide anion, and organic peroxide [9]. These ROS can cause cellular damage if they are not detoxified by antioxidant systems. Increased mitochondrial ROS generation and the disturbance of peroxiredoxin (Prx) production in cancer cells may lead to oxidative stress and the induction of apoptosis. The Prx system is a cellular defense system against oxidative stress. Mitochondria in cancer cells are known to contain high levels of Prx III and Prx V [10–14]. However, Prx V founds in various compartments in the cell, including mitochondria, peroxisome and nucleus [15–17]. Moreover, mitochondria are a major site of hydrogen peroxide generation in cells [18]. Prx III prefers to scavenge hydrogen peroxide, which will be the target for up to 90% of
H₂O₂. In contrast, Prx V behaves more effectively as a scavenger of peroxynitrite [19–22]. Here, we discuss the role of the mitochondrial Prx III antioxidant system being exclusively present in mitochondria as a potential target for cancer therapy, and examine the effects of antioxidant proteins on ROS in mitochondria. We hope that this review article will advance our understanding of mitochondrial biology in cancer, and provide a basis for designing new strategies to achieve effective cancer treatment.

2. Mitochondrion-Targeting Cancer Therapy

Mitochondria are known to play a key role in apoptosis and to trigger cell death via several mechanisms, including the disruption of electron transport and energy metabolism, the release or activation of proteins that mediate apoptosis, and the alteration of the cellular redox potential [23–25]. Apoptotic cell death is characterized by a host of morphological and biochemical features, including mitochondrial outer membrane permeabilization (MOMP) and the release of pro-apoptotic proteins [26]. In response to pro-apoptotic stimuli, including ROS and Ca²⁺ overload, the permeability transition pore complex (PTPC) assumes a high-conductance state that deregulates the entry of small solutes into the mitochondrial matrix along their electrochemical gradients[1]. This mitochondrial permeability transition (MPT) results in immediate dissipation of the mitochondrial membrane potential and osmotic swelling of the mitochondrial matrix. As the surface area of the inner membrane considerably exceeds that of the outer membrane, the MPT eventually leads to MOMP (Figure 1). The MPT can be triggered by agents that increase cytosolic Ca²⁺ concentrations or stimulate ROS generation. The mitochondrial pore, a putative multimeric complex situated at mitochondrial contact sites, mediates the MPT. Based on biochemical evidence, the standard model for the PT pore consists of a voltage-dependent anion channel (VDAC) in the outer membrane, adenine nucleotide translocase (ANT), and cyclophilin D (CypD) in the matrix (Figure 1A; [27,28]. As shown in Figure 1A, the VDAC has always been considered a key component of the PTPC. However, considerable recent evidence suggests that the conclusions of standard model studies were incorrect (Figure 1B). Closure of the VDAC has been shown to increase the influx of Ca²⁺ into mitochondria [29], which has the net effect of inducing, rather than inhibiting, the MPT. Moreover, recent genetic studies have confirmed a regulatory role for CypD in the MPT [30,31]. Mice lacking ANT or the VDAC still exhibit a classical MPT response that is inhibited by cyclosporine A [32,33]. Thus, current genetic strategies indicate that only CypD functions as a necessary effector of the MPT, and suggest that alternative proteins and/or mechanisms must play roles in mitochondrial-dependent cell mortality via the PT pore. Because two proposed models for the PT pore have not yet been fully elucidated, the PT pore is not sufficiently well characterized to be a target for anticancer drugs. Although the exact molecular identity of the effectors of the MPT is under debate, it is agreed to be a crucial step in cell death.
Figure 1. Molecular mechanisms of the mitochondrial permeability transition (MPT) and mitochondrial apoptotic cell death. (a) Mitochondrial outer membrane permeabilization (MOMP) leads to apoptogenic protein release. Bax or Bak forms a pore in the OM after activation by a BH3-only protein such as Bid (after the truncation of Bid by caspase-8). The opening of the PT pore allows an influx of water and ions into the matrix, causing matrix swelling. This leads to rupture of the OM and the release of intermembrane space (IMS) proteins. The permeability transition pore complex (PTPC) is a highly dynamic supramolecular entity that can comprise a voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT), and cyclophilin D (CypD). Other proteins, including the peripheral benzodiazepine receptor (PBR), hexokinase (HK), and creatine kinase (CK), may also be associated with the PTPC. It is not clear whether the PTPC has a role under physiological conditions. Mitochondria exhibit a high mitochondrial transmembrane potential, which is generated by the respiratory chain and exploited for ATP generation. It has been proposed that under these conditions the PTPC exists in a low-conductance state, thereby contributing to the exchange of small metabolites between the cytosol and the mitochondrial matrix, a process that is predominantly mediated by mitochondrial solute carriers. However, under pathological conditions characterized by a high Ca\(^{2+}\) concentration, increased oxidative stress, low levels of ATP, and mitochondrial depolarization, the complex forms an open pore between the inner and outer membranes, allowing the free diffusion of solutes across the membranes. The opening of the PTPC results in mitochondrial swelling, mitochondrial Ca\(^{2+}\) efflux, and the release of apoptogenic proteins such as cytochrome c and Smac from the IMS. (b) Alternative models proposed in light of recent findings in gene-targeted mice. A VDAC is no longer part of the model and it appears that an OM component may not be necessary for this process. ANT now appears to be more of a regulatory protein, and only CypD remains as an established component. In contrast, the mitochondrial phosphate carrier (PiC) has been added to the model as a candidate component of the pore-forming unit of the MPT pore.
Because most cancer cells have increased resistance to the activation of MOMP and escape apoptosis as a result of various modifications in apoptosis regulators, including Bcl-2 family members, p53, and caspases [34], various mitochondrion-targeted cancer treatment strategies have been developed in the last decade [35,36]. These strategies focused mainly on the development of compounds that regulate mitochondrial Bcl-2 family proteins, modulate MOMP and hyperpolarized mitochondria inner membrane potential sensing, or target high levels of ROS and overexpressed receptors in cancer cells [35]. An excellent previous review by Fulda et al. summarized examples of mitochondrion-targeted compounds (Table 1); [36]. Numerous molecules that are currently in use or being tested in clinical trials act on mitochondria [37]. Clinically approved anticancer drugs such as etoposide [38], paclitaxel [39], and vinorelbine [40], as well as an increasing number of experimental anticancer drugs, including ceramide [41], MKT077 [42], and CD437 [43], have been found to act directly on mitochondria to trigger apoptosis. Several classes of compounds with distinct mechanisms of action can stimulate the MPT and mitochondrial apoptosis in cancer cells, pointing to some functional redundancy and suggesting the likely existence of alternative biochemical cascades leading to mitochondrial membrane permeabilization. Thus, the selective targeting of cancer cells using mitochondrial-targeted agents is likely to attract great interest. A better understanding of the key pathophysiological differences between mitochondria in cancer cells and their counterparts in non-cancerous cells will undoubtedly be instrumental in increasing the level of selectivity of mitochondrion-targeted anticancer agents. Nevertheless, a limited number of studies have evaluated agents targeting the mitochondrial ROS regulatory system.

**Table 1. Examples of mitochondrion-targeted compounds.**

| Class                              | Compound            | Action(s)/targets                  |
|------------------------------------|---------------------|------------------------------------|
| **Modulators of the BCL-2 protein family** |                     |                                    |
| A-385358                           | BCL-X<sub>i</sub>   |                                    |
| ABT-263, ABT-737                   | BCL-2, BCL-X<sub>i</sub>, BCL-W |                                    |
| AT-101                             | BCL-2, BCL-X<sub>i</sub>, BCL-W, MCL1 |                                |
| GX15-070 (Obatoclax)               | BCL-2, BCL-X<sub>i</sub>, BCL-W, MCL1 |                                |
| HA14-1                             | BCL-2               |                                    |
| **Metabolic inhibitors**           |                     |                                    |
| 3-bromopyruvate                    | HK2–VDAC interaction |                                |
| Dichloroacetate                    | PDK inhibition      |                                |
| HK2 peptide                        | HK2–VDAC interaction |                                |
| LDH-A shRNA                        | LDH-A               |                                |
| Methyl jasmonate                   | HK2–VDAC interaction |                                |
| SB-204990                          | ATP citrate lyase   |                                |
| Orlistat                           | Fatty acid synthase |                                |
| Soraphen A                         | Acetyl-CoA carboxylase inhibition |                                |
| 2-deoxy-D-glucose                  | HK2                 |                                |
Table 1. Cont.

| VDAC- and/or ANT-targeting agents | Clodronate | ANT inhibition |
|-----------------------------------|------------|---------------|
|                                   | GSAO       | ANT cross linker |
|                                   | Lonidamine | ANT ligand    |
|                                   | PK11195    | PBR ligand    |
| Arsenic trioxide                  |            | ANT ligand, ROS production |
|                                   | Retinoids  |                |
| All-trans-retinoic acid           |            | ANT ligand    |
| CD437                             |            | Permeability transition pore complex |
| ST1926                            |            | Perturbation of Ca²⁺ homeostasis |
| HSP90 inhibitors                  | Gamitrinibs | Mitochondrial HSP90 ATPase inhibition |
| PU24FCI, PU-H58, PU-H71           |            | HSP90 inhibition |
| Shepherdin                        |            | Inhibition of the HSP90–survivin interaction |
| Natural compounds and derivatives | α-tocopheryl succinate | Ubiquinone-binding sites in respiratory complex II |
| Betulinic acid                    |            | Permeability transition pore complex |
| Resveratrol                       |            | F₁-ATPase     |

ANT, adenine nucleotide translocase; BCL-2, B-cell lymphoma protein 2; BCL-W, also known as BCL2-like protein 2 (BCL2L2); BCL-XL, also known as BCL2-like protein 1 (BCL2L1); CD437, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid; HA14-1, 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate; GPX, glutathione peroxidase; GSH, reduced glutathione; HK, hexokinase; HSP90, heat shock protein, 90 kDa; LDH-A, lactate dehydrogenase A; MCL1, myeloid cell leukemia sequence 1; PBR, peripheral benzodiazepine receptor; PDK, pyruvate dehydrogenase kinase; PU24FCI, 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-(pent-4-ynyl)-9H-purin-6-amine; PU-H58 (8-(6-bromobenzo[d][1,3]dioxol-5-ythio)-9-(pent-4-ynyl)-9H-purin-6-amine; PU-H71, 8-(6-iodobenzo[d][1,3]dioxol-5-ythio)-9-(3-isopropyl amino)propyl)-9H-purin-6-amine; ROS, reactive oxygen species; shRNA, short hairpin RNA; SOD, superoxide dismutase; ST1926, (E)-3-(4′-hydroxy-3′-adamantylbiphenyl-4-yl)acrylic acid; VDAC, voltage-dependent anion channel. Adapted from [36] with permission.

3. Regulation of the Mitochondrial Antioxidant System

Since the discovery that electron leakage and incomplete reduction of oxygen occur in the respiration chain [44], mitochondria have been considered a major contributor to cellular oxidative damage due to their generation of ROS. Moreover, mitochondria possess a multilevel network of enzymatic and non-enzymatic antioxidant systems for the detoxification of H₂O₂ (Figure 2). The biological significance of mitochondrial ROS has been highlighted by the targeted deletion or overexpression of antioxidant proteins. For example, superoxide dismutase (SOD) 2, thioredoxin (Trx) 2, Prx III and Prx V have been reported to constitute a novel antioxidant defense system that detoxifies ROS generated in mitochondria [45,46]. Prx3-knockout (KO) mice were showed aberrant regulation of oxidative stress. Proteomic analysis and gene expression analysis in adipocytes from Prx3-KO mice also showed defect in mitochondria biogenesis along with enzymes involved in glucose/lipid metabolism and oxidative phosphorylation [47]. Trx2-KO mice have an embryonic lethal phenotype [48]. SOD2-KO mice typically die within 3 weeks of birth as a result of severe
neurodegeneration and mitochondrial oxidative damage [49,50]. Prx V was associated with the mitochondrial pathway of apoptosis and calcium loading capacity of mitochondria, as well as changes in mitochondrial morphology [14]. The homozygous glutathione peroxidase (GPx)1-KO mice appeared healthy and manifested no increased sensitivity to hyperoxia or increased levels of protein carbonyl groups or lipid peroxides [51]. However, a protective role for GPx1 became apparent, when the GPx1 KO and control mice were subjected to extreme oxidative stress such as that associated with ischemia-reperfusion injury or treatment with paraquat or a bolus of H2O2 [52,53]. In mammalian cells, GPx1 is the major isoform and is expressed in all tissues; it is localized predominantly in the cytosol, but a small proportion (10%) of GPx1 molecules is also present in the mitochondrial matrix [51,54,55]. Thereby, it remains unclear whether the effect of GPx1-KO under these conditions was attributable to the absence of the enzyme form the cytosol or from mitochondria, or from both. To date, the multiplelevel network of antioxidant system in mitochondria has been extensively discussed in a number of recent publications. Based on these studies, mitochondrial-targeted agents emerge as a means to selectively target tumors. Here, we provide a comprehensive compendium on the mitochondrial-targeted compounds for the treatment of human cancer.

Multiple compounds act on components of the antioxidant system to induce ROS generation and apoptosis. Reportedly, the increase in intrinsic ΔΨm correlates with increased malignancy (apoptosis resistance and tumor progression) [56], suggesting that cytotoxic agents that permeabilize the mitochondrial membrane, such as compounds that induce the overproduction of ROS, are effective anticancer drugs in cancer cells. The inhibition of antioxidant systems is an alternative way to induce ROS accumulation. Compounds that inhibit antioxidant systems include the SOD inhibitors 2-methoxyestradiol, choline tetrathiomolybdate (ATN-224), and mangafodipir; buthionine sulfoximine, imexon, and phenylethyl isothiocyanate (PEITC), which cause glutathione (GSH) inhibition or depletion; and menadione, motexafin gadolinium, β-lapachone, elesclomol (STA-4783), arsenic trioxide, parthenolide, dimethylamino-parthenolide (DMAPT), and bistetrahydrofuranic acetogenins, which induce ROS production (Table 2).

2-methoxyoestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis, and selectively kills human leukemia cells by inhibiting SOD, thereby causing superoxide accumulation [57]. Several Phase I/II trials in patients with solid malignancies or multiple myeloma have demonstrated that 2-methoxyoestradiol is well tolerated and causes disease stabilization [58–60]. Similar effects are produced by the intracellular copper-chelating agent ATN-224 [61]. ATN-224 is an orally bioavailable, second-generation tetrathiomolybdate analog with potential antiangiogenic and antineoplastic activities. Mangafodipir is a SOD mimic with catalase and GSH reductase activities. Consisting of manganese ions chelated to fodipir (dipyridoxyl diphosphate; DPDP), it scavenges oxygen free radicals such as the superoxide anion, hydrogen peroxide, and the hydroxyl radical, potentially preventing oxygen free radical damage to macromolecules such as DNA and minimizing oxygen free radical–related chemotoxicity in normal tissues. In cancer cells, it has been shown to increase H2O2 levels and to potentiate the antitumor activity of paclitaxel in a mouse xenotransplant colon cancer model [62]. Moreover, it is being tested in a Phase II trial in patients with colon cancer.

Buthionine sulfoximine irreversibly inhibits γ-glutamylcysteine synthetase. It increases ROS levels by inhibiting the synthesis of reduced GSH [63]. Imexon depletes the GSH pool due to its
thiol-binding activity [64]. Buthionine sulfoximine and the alkylating agent melphalan are being evaluated in Phase II clinical trials in patients with melanoma or relapsed/refractory ovarian cancer. PEITC, which is thiol modifier, preferentially causes ROS overproduction, mitochondrial oxidative damage, MOMP, and apoptosis in cancer cells, presumably due to their increased ROS levels [65,66]. The compound is known effects on the selenoprotein thioredoxin reductase, glutathione reductase and intracellular GSH levels. Moreover, Prx III is early oxidized after exposure of this compound [67].

**Figure 2.** Antioxidant system for H$_2$O$_2$ removal in mitochondria. Reactive oxygen species (ROS), in the form of O$_2^-$ and H$_2$O$_2$, have multiple intra- and extramitochondrial sources. O$_2^-$ is converted to H$_2$O$_2$ through the action of superoxide dismutase (SOD) 2 and /or spontaneous dismutation. H$_2$O$_2$ can diffuse into the mitochondrial matrix, where it is removed via three systems/mechanisms: 1) peroxiredoxin (Prx) III coupled to thioredoxin (Trx) 2 and Trx reductase (TrxR) 2; 2) glutathione peroxidase (GPx) coupled to glutathione (GSH) and GSH reductase (GR); and 3) non-enzymatic scavenging by redox compounds. The peroxidatic cysteine Cys-SH is selectively oxidized by H$_2$O$_2$ to Cys-SOH, which then reacts with the resolving cysteine Cys-SH of the other subunit in the homodimer to form an intermolecular disulfide bond. Subsequently, the disulfide bond is specifically reduced by Trx2, which in turn receives reducing equivalents from nicotinamide adenine dinucleotide phosphate (NADPH) via TrxR2. The Cys-SOH generated is oxidized to Cys-SO$_2$H, leading to peroxidase inactivation. Reactivation of the enzyme is achieved by reduction of the Cys-SO$_2$H moiety in a reaction that requires ATP hydrolysis and is catalyzed by sulfiredoxin (Srx), with reducing equivalents provided by physiological thiols (RSH) such as GSH and Trx. The respiration substrates malate/glutamate and succinate provide energy in the form of reducing covalents (NADPH), which are maintained by ΔΨm-dependent transhydrogenase and tricarboxylic acid (TCA) cycle enzymes. NADPH is utilized by the reductases in the peroxidase system (TrxR and GR) to reduce disulfide bonds formed in proteins during the detoxification of H$_2$O$_2$.
Table 2. Development and clinical status of anti-cancer drugs targeting the mitochondrial oxidative system.

| Target          | Compound                                                                 | Action(s)/target(s)                  | Development status (ClinicalTrials.gov)                                              | Ref. |
|-----------------|--------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------|------|
| SOD             | 2-methoxyestradiol                                                      | SOD inhibition                       | Completed: Phase I in solid tumors                                                   | [68,69]|
|                 | ATN-224                                                                 | SOD inhibition                       | Closed: Phase II in combination with temozolomide in advanced melanoma               | [61] |
|                 | Mangafodipir                                                           | SOD mimic                            | Active: Phase II in patients who have moderate oxaliplatin neuropathy                 | [62] |
|                 | Buthionine sulfoximine (BSO)                                            | GSH synthesis inhibition             | Active: Phase I in resistant or recurrent neuroblastoma                               | [63] |
|                 | Imexon (Amplimexon)                                                    | GSH depletion                         | Active: Phase II in follicular and aggressive lymphomas                               | [64] |
|                 | PEITC                                                                   | GSH depletion, GPx inhibition         | Active: Phase II in preventing lung cancer in smokers                                 | [65] |
|                 | Menadione                                                              | ROS production                        | Closed: Phase I in patients treated with EGFR inhibitors                               | [34] |
|                 | Motexafin gadolinium                                                    | ROS production                        | Not yet open (active): Phase IV to determine the efficacy of biennial screening with MRI in breast cancer                      | [70] |
|                 | β-lapachone (ARQ 501)                                                  | ROS production                        | Active: Phase II in diffuse pontine gliomas, malignant brain tumors, and stage IV renal cell carcinoma etc.                  | [71] |
|                 | STA-4783 (Elesclomol sodium)                                            | ROS production                        | Completed: Phase II in pancreatic cancer (in combination with gemcitabine), metastatic leiomyosarcoma and metastatic squamous cell cancer of the head and neck; Phase I in combination with docetaxel in carcinoma | [72,73]|
Menadione binds to and inhibits the activity of the PTPs that dephosphorylate and inactivate epidermal growth factor receptor (EGFR) and erythroblastic leukemia viral oncogene homolog 2 (ErbB2) in human keratinocytes. Local reversal of EGFR and ErbB2 inhibition associated with the systemic administration of EGFR inhibitors may help alleviate EGFR inhibitor–mediated skin toxicity. Menadione undergoes futile redox cycles in the respiratory chain. Thiol cross-linking agents, such as diamide, bismaleimido-hexane, and dithiodipyridine, cause ANT thiol oxidation and can bypass B-cell lymphoma 2 (BCL-2)–mediated cytoprotection [78,79]. β-lapachone is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), causing futile oxidoreduction that generates high levels of superoxide, and is currently under clinical investigation, as a monotherapy or in combination with gemcitabine, in patients with pancreatic and head-and-neck cancer. STA-4783 induces oxidative stress, increasing levels of ROS such as hydrogen peroxide in both cancer cells and normal cells. Because tumor cells have elevated levels of ROS compared with normal cells, the increase in oxidative stress beyond baseline levels elevates ROS levels beyond sustainable levels, exhausting tumor cell antioxidant capacity. This may result in the activation of the mitochondrial apoptosis pathway [72].

Arsenic trioxide is a small-molecule arsenic compound with antineoplastic activity. Although the mechanism of action of arsenic trioxide is not completely understood, it causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-α (PML/RARα) fusion protein; induces apoptosis in acute promyelocytic leukemia cells and many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. Parthenolide is a sesquiterpene lactone that can cause allergic reactions. It has anti-inflammatory, antimicrobial, and anticancer properties, activates the tumor suppressor p53, and inhibits nuclear factor-kappa B (NF-κB) and the signal transducer and activator of transcription 3 (STAT-3; [80]). It also induces intracellular oxidative stress, which is manifested by increased ROS levels and activation of c-Jun N-terminal kinase (JNK). The water-soluble parthenolide analog DMAPT, which swiftly kills leukemic stem cells from both myeloid and lymphoid leukemias, is also highly cytotoxic to bulk leukemic cell populations. Molecular studies have found that the key activities of DMAPT include the induction of oxidative stress responses, the inhibition of NF-κB, and the activation of p53 [75]. Natural bistetrahydrofuranic acetogenins show growth inhibitory activity against human breast, lung, liver, and colon cell lines [77]. Recently, structure–activity relationship (SAR) analysis has led to the synthesis of promising new derivatives with improved antitumor

| ROS over-production | Arsenic trioxide (Trisenox) | ROS production, ANT ligand | Active: Phase IV in relapsed promyelocytic leukemia etc. (13 ongoing clinical trials) | [74] |
|---------------------|----------------------------|--------------------------|-----------------------------------------------|-----|
|                     | DMAPT                      | ROS production           | Discovery                                      | [75] |
|                     | Parthenolide               | ROS production           | Discovery                                      | [76] |
|                     | Bistetrahydrofuranic acetogenins | ROS production   | Discovery                                      | [77] |

Table 2. Cont.
properties. However, trials of numerous ROS-regulating compounds, including menadione and STA-4783, have been discontinued due to safety concerns.

4. Peroxiredoxin III: A Potential Mitochondrial Target for Cancer Therapy

Peroxiredoxins are a family of enzymes that catalyze the reduction of hydrogen peroxide and hydroperoxides to water and alcohol, respectively [81,82]. The six isoforms of mammalian Prx (I–VI) are classified into three subfamilies (2-Cys, atypical 2-Cys, and 1-Cys) based on the number and position of the cysteine (Cys) residues that participate in catalysis. Also, the Prxs can be categorized by their subcellular localization; Prx I, II and VI found in the cytoplasm, Prx IV in the endoplasmic reticulum, Prx III in the mitochondria, and Prx V found in various compartments in the cell, including peroxisomes and mitochondria. Prx I–IV (2-Cys Prx subfamily) have two conserved Cys residues. In the catalytic cycle of the 2-Cys Prxs, the conserved N-terminal Cys sulfhydryl (Cys-SH) is first oxidized by peroxides to Cys sulfenic acid (Cys-SOH), which then reacts with the conserved COOH-terminal Cys-SH of the other subunit in the homodimer to form a disulfide bond. The Prx V is an atypical 2-Cys Prx that becomes oxidized at the peroxidatic cysteine (Cys48) to a sulfenic acid, which condenses with a resolving cysteine (Cys152) within the same polypeptide to form an intramolecular disulfide linkage [16]. In contrast, Prx VI has only one Cys residue involved in the peroxidase activity Prx VI (1-Cys), and unlike the other members, does not use thioredoxin as a reductant. The N-terminal Cys-SH of Prx VI is readily oxidized, but the resulting Cys-SOH does not form a disulfide because of the unavailability of another Cys-SH nearby [83,84]. As the physiological reductant, Prx VI utilizes GSH via the formation of disulfide with GSH mediated by GST.

The hyper-proliferative property of cancer cells is known to be associated with increased production of intracellular ROS [85]. Moreover, many reports have claimed an association between alterations in the protein level of Prx isoforms. Such Prxs serve divergent functions, such as protecting cells against oxidative stress, regulating cell signaling associated with H2O2, and influencing cell differentiation and proliferation, immune responses, and apoptosis [82,86,87]. Recent studies reported elevated expression of Prx I in several human cancers, including non-small cell lung cancer (NSCLC) [88,89], oral cancer [90], breast cancer [11], and liver cancer [91]. Prx II levels are increased in breast, mesothelioma, and head-and-neck cancers [10,92]. While increased Prx II expression rendered leukemia and stomach cancer cells resistant to various chemotherapeutic agents [93,94], downregulation of Prx II sensitized head-and-neck cancer cells to radiation and gastric carcinoma to cisplatin [95,96]. Moreover, downregulation of Prx II enhances apoptotic cell death induced by tumor necrosis factor (TNF)-α and TNF-related apoptosis-inducing ligand (TRAIL). Importantly, cytosolic Prx II regulates caspase-8 activation, but exerts no influence on sustained JNK activation [97]. Downregulation of Prx I was shown to sensitize lung cancer cells to radiation and reduce metastasis [98,99], and to increase the sensitivity of prostate cells to androgen ablation treatment [100]. Prx IV is decreased in stomach cancers [101]; may play an important role in protecting cells from ionizing radiation-induced apoptosis in head-and-neck squamous cell carcinoma [102]; in lung cancer cells, Prx IV interacts with surfiredoxin and the interaction axis leads to acceleration of tumor growth and metastasis formation in vivo [103]. Prx V represented antioxidant functions in the lung cartilage, and brain [104–106]. Overexpression of Prx V was reported to protect Chinese hamster ovary cells
from oxidative stress; suppressed p53-dependent apoptosis [107]; promoted differentiation, and reduced apoptosis in the mice muscle cells [108] and human tendon cells [109]. However, it still remains unknown whether the function of this protein is restricted to its antioxidant activity, and position of major compartments to protect cells from cell death. Prx VI is decreased in a mouse that is susceptible to experimental atherosclerosis [110] and is elevated in the spinal cord of mice expressing mutant superoxide dismutase1 [111]; in brains of patients with parkinsonian dementia [112], sporadic Creutzfeldt-Jacob disease [113], and Pick disease [114]; in the healing edge of skin wounds [115]; and in experimental cellular premature senescence [116]. Especially, it is elevated in lungs with malignant mesothelioma [10] or high grade squamous cell carcinoma [117].

Like cytosolic Prx I and Prx II, mitochondrial Prx III is overexpressed in hepatocellular carcinoma [12] and breast cancer [11]. The overexpression of Prx III can protect cells against oxidative injury [13,118], whereas the deletion of Prx III in HeLa cells can increase intracellular levels of H$_2$O$_2$ and sensitize cells to the induction of apoptosis by staurosporine and TNF-$\alpha$ [119]. Furthermore, the abundance of Prx III was found to be reduced in the brains of patients with Alzheimer’s disease and Down syndrome, possibly rendering the neuronal cells of these patients more vulnerable to cell death [120].

The role of Prx III in the scavenging of mitochondrial H$_2$O$_2$ has recently been emphasized. Originally cloned from murine erythroleukemia cells, Prx III has been identified as a gene induced by oncogenic c-Myc [121]. Its specific localization to mitochondria [122,123] suggests that Prx III, together with its mitochondrion-specific electron suppliers Trx2 and Trx reductase (TrxR) 2 [124,125], might provide a primary line of defense against H$_2$O$_2$ produced by the mitochondrial respiratory chain [126,127], as SOD2 does against the superoxide radical. In the presence of excess H$_2$O$_2$, Prx III is highly sensitive to oxidative inaction. Hyperoxidation of Prx III has been observed in cultured cells following prolonged exposure to high levels of H$_2$O$_2$ or drugs that generate H$_2$O$_2$ [128–130]. Moreover, hyperoxidized Prx III is reduced more slowly than hyperoxidized Prx I and II in the cytoplasm [129] and the slow reduction will enable the hyperoxidized form of Prx III to accumulate under certain conditions. Therefore, hyperoxidized Prx III formation by H$_2$O$_2$ leads to an increase in mitochondrial H$_2$O$_2$ and that this may influence the progression of apoptosis.

In addition, sulfiredoxin (Srx) plays a crucial role by reducing hyperoxidized Prx III via translocation into mitochondria. Noh et al. reported that the overexpression of mitochondrion-targeted Srx efficiently promotes the restoration of Prx III and results in cellular resistance to apoptosis, with enhanced elimination of mitochondrial H$_2$O$_2$ and decreased rates of $\Delta$$\Psi$m collapse [131]. Thus, a Trx-related antioxidant system composed of Trx2, TrxR2, and Prx III has been closely associated with the regulation of apoptosis and the redox control of MPT pores for the release of cytochrome $c$ [79,94,132]. However, rare attempts to characterize Prx III and its electron suppliers have produced intriguing results that demonstrate the removal of exogenous ROS by actively respiring mitochondria.

5. Outlook and Future Perspectives

Most of the currently used cytotoxic anticancer therapeutics have no clear-cut cell specificity, yet tend to kill tumor cells more efficiently than normal cells. With rare exceptions, single drugs at clinically tolerable doses have not been able to cure cancer. Prolonged drug exposure may result in
cumulative toxicity. The clinical efficacy of chemotherapy must be enhanced, its attendant toxicity reduced, and resistance overcome. To overcome multidrug resistance in cancer cells, recent chemotherapeutics could be used in combination with other molecules. In the 1960s and early 1970s, drug combination regimens were developed based on the known biochemical actions of available anticancer drugs, rather than on their clinical efficacy. However, such regimens were largely ineffective [133,134]. The era of effective combination chemotherapy began when a number of active drugs of different classes became available for use in combination to treat acute leukemia and lymphomas. After this initial success with hematologic malignancies, combination chemotherapy was applied to the treatment of most solid tumors.

Structural and functional mitochondrial alterations associated with malignant transformation seem to be phenomena common to many types of cancer. Most classical anticancer agents engage signaling pathways that lie upstream of mitochondria and converge on mitochondria due to their role as integrators of pro-death and pro-survival signals. MOMP occurs as a consequence of upstream signaling events that are frequently deregulated in human cancers and that become resistant to a number of conventional therapeutic strategies targeting upstream MOMP regulators. Anticancer drugs that target mitochondria have the potential to bypass the resistance mechanisms that evolved in response to treatment with conventional chemotherapeutics. The combined use of mitochondrion-targeted agents with conventional chemotherapeutics and other chemotherapeutic drugs, such as ROS scavenger inhibitors or ROS inducers, may be necessary to achieve maximum efficacy. The pharmacological depletion of ROS scavengers in cancer cells markedly reduces their clonogenicity and results in radiosensitization. As mentioned above, recent studies have shown that the overexpression of Prx III and its electron donors can protect cells, whereas their depletion induced cell death in cancer cells. Therefore, drugs targeting Prx III and the mitochondrion-specific electron suppliers Trx2, TrxR2, and Srx may potentially be administered in combination with various chemotherapeutic agents, including cisplatin, paclitaxel, and etoposide. However, caution must be exercised to prevent a potential increase in toxic side effects. A comprehensive understanding of mitochondrial biology in cancer cells and the interaction between cellular metabolism and drug action is essential in the development of mitochondrion-targeted agents for cancer treatment.

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health, Welfare and Family affairs, Republic of Korea (0920040) and the Priority Research Centers Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2010-0020224).

Conflict of Interest

The authors declare no conflict of interest.
References

1. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87, 99–163.

2. Galluzzi, L.; Joza, N.; Tasdemir, E.; Maiuri, M.C.; Hengartner, M.; Abrams, J.M.; Tavernarakis, N.; Penninger, J.; Madeo, F.; Kroemer, G. No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008, 15, 1113–1123.

3. Galluzzi, L.; Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008, 135, 1161–1163.

4. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008, 18, 165–173.

5. Modica-Napolitano, J.S.; Singh, K.K. Mitochondrial dysfunction in cancer. Mitochondrion 2004, 4, 755–762.

6. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314.

7. Weinhouse, S. On respiratory impairment in cancer cells. Science 1956, 124, 267–269.

8. Weinberg, F.; Hamanaka, R.; Wheaton, W.W.; Weinberg, S.; Joseph, J.; Lopez, M.; Kalyanaraman, B.; Mutlu, G.M.; Budinger, G.R.; Chandel, N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107, 8788–8793.

9. Reed, D.J. Glutathione: toxicological implications. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 603–631.

10. Kinnula, V.L.; Lehtonen, S.; Sormunen, R.; Kaarteenaho-Wiik, R.; Kang, S.W.; Rhee, S.G.; Soini, Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 2002, 196, 316–323.

11. Noh, D.Y.; Ahn, S.J.; Lee, R.A.; Kim, S.W.; Park, I.A.; Chae, H.Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001, 21, 2085–2090.

12. Choi, J.H.; Kim, T.N.; Kim, S.; Baek, S.H.; Kim, J.H.; Lee, S.R.; Kim, J.R. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002, 22, 3331–3335.

13. Nonn, L.; Berggren, M.; Powis, G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res. 2003, 1, 682–689.

14. Kropotov, A.; Gogvadze, V.; Shupliakov, O.; Tomilin, N.; Serikov, V.B.; Tomilin, N.V.; Zhivotovsky, B. Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp. Cell Res. 2006, 312, 2806–2815.

15. Knoops, B.; Clippe, A.; Bogard, C.; Arsalane, K.; Wattiez, R.; Hermans, C.; Duconseille, E.; Falmagne, P.; Bernard, A. Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. J. Biol. Chem. 1999, 274, 30451–30458.

16. Seo, M.S.; Kang, S.W.; Kim, K.; Baines, I.C.; Lee, T.H.; Rhee, S.G. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. J. Biol. Chem. 2000, 275, 20346–20354.
17. Kropotov, A.; Usmanova, N.; Serikov, V.; Zhivotovsky, B.; Tomilin, N. Mitochondrial targeting of human peroxiredoxin V protein and regulation of PRDX5 gene expression by nuclear transcription factors controlling biogenesis of mitochondria. *FEBS J.* 2007, 274, 5804–5814.
18. Murphy, M.P. How mitochondria produce reactive oxygen species. *Biochem. J.* 2009, 417, 1–13.
19. Cao, Z.; Bhella, D.; Lindsay, J.G. Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state. *J. Mol. Biol.* 2007, 372, 1022–1033.
20. Manta, B.; Hugo, M.; Ortiz, C.; Ferrer-Sueta, G.; Trujillo, M.; Denicola, A. The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2. *Arch. Biochem. Biophys.* 2009, 484, 146–154.
21. Trujillo, M.; Clippe, A.; Manta, B.; Ferrer-Sueta, G.; Smeets, A.; Declercq, J.P.; Knoops, B.; Radi, R. Pre-steady state kinetic characterization of human peroxiredoxin 5: taking advantage of Trp84 fluorescence increase upon oxidation. *Arch. Biochem. Biophys.* 2007, 467, 95–106.
22. Dubuisson, M.; Vander Stricht, D.; Clippe, A.; Etienne, F.; Nauser, T.; Kissner, R.; Koppenol, W.H.; Rees, J.F.; Knoops, B. Human peroxiredoxin 5 is a peroxynitrite reductase. *FEBS Lett.* 2004, 571, 161–165.
23. Gulbins, E.; Dreschers, S.; Bock, J. Role of mitochondria in apoptosis. *Exp. Physiol.* 2003, 88, 85–90.
24. Hiendleder, S.; Schmutz, S.M.; Erhardt, G.; Green, R.D.; Plante, Y. Transmitochondrial differences and varying levels of heteroplasmy in nuclear transfer cloned cattle. *Mol. Reprod. Dev.* 1999, 54, 24–31.
25. Waterhouse, N.J.; Goldstein, J.C.; Kluck, R.M.; Newmeyer, D.D.; Green, D.R. The (Holey) study of mitochondria in apoptosis. *Methods Cell Biol.* 2001, 66, 365–391.
26. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link. *Nat. Rev. Mol. Cell Biol.* 2003, 4, 552–565.
27. Zamzami, N.; Kroemer, G. The mitochondrion in apoptosis: how Pandora's box opens. *Nat. Rev. Mol. Cell Biol.* 2001, 2, 67–71.
28. Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. *Physiol. Rev.* 2008, 88, 581–609.
29. Tan, W.; Colombini, M. VDAC closure increases calcium ion flux. *Biochim. Biophys. Acta* 2007, 1768, 2510–2515.
30. Baines, C.P.; Kaiser, R.A.; Purcell, N.H.; Blair, N.S.; Osinska, H.; Hambleton, M.A.; Brunskill, E.W.; Sayen, M.R.; Gottlieb, R.A.; Dorn, G.W.; Robbins, J.; Molken, J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. *Nature* 2005, 434, 658–662.
31. Schinzel, A.C.; Takeuchi, O.; Huang, Z.; Fisher, J.K.; Zhou, Z.; Rubens, J.; Hetz, C.; Danial, N.N.; Moskowitz, M.A.; Korsmeyer, S.J. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. *Proc. Natl. Acad. Sci. USA* 2005, 102, 12005–12010.
32. Kokoszka, J.E.; Waymire, K.G.; Levy, S.E.; Sligh, J.E.; Cai, J.; Jones, D.P.; MacGregor, G.R.; Wallace, D.C. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. *Nature* 2004, 427, 461–465.
33. Baines, C.P.; Kaiser, R.A.; Sheiko, T.; Craigen, W.J.; Molkentin, J.D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. *Nat. Cell Biol.* **2007**, *9*, 550–555.

34. Costantini, P.; Belzacq, A.S.; Vieira, H.L.; Larochette, N.; de Pablo, M.A.; Zamzami, N.; Susin, S.A.; Brenner, C.; Kroemer, G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. *Oncogene* **2000**, *19*, 307–314.

35. Fantin, V.R.; Leder, P. Mitochondriotoxic compounds for cancer therapy. *Oncogene* **2006**, *25*, 4787–4797.

36. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. *Nat. Rev. Drug Discov.* **2010**, *9*, 447–464.

37. Pathania, D.; Millard, M.; Neamati, N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. *Adv. Drug Deliv. Rev.* **2009**, *61*, 1250–1275.

38. Robertson, J.D.; Gogvadze, V.; Zhivotovsky, B.; Orrenius, S. Distinct pathways for stimulation of cytochrome c release by etoposide. *J. Biol. Chem.* **2000**, *275*, 32438–32443.

39. Kidd, J.F.; Pilkington, M.F.; Schell, M.J.; Fogarty, K.E.; Skepper, J.N.; Taylor, C.W.; Thorn, P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. *J. Biol. Chem.* **2002**, *277*, 6504–6510.

40. Chinnery, P.F.; Taylor, G.A.; Howell, N.; Andrews, R.M.; Morris, C.M.; Taylor, R.W.; McKeith, I.G.; Perry, R.H.; Edwardson, J.A.; Turnbull, D.M. Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. *Neurology* **2000**, *55*, 302–304.

41. Stover, T.C.; Sharma, A.; Robertson, G.P.; Kester, M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. *Clin. Cancer Res.* **2005**, *11*, 3465–3474.

42. Propper, D.J.; Braybrooke, J.P.; Taylor, D.J.; Lodi, R.; Styles, P.; Cramer, J.A.; Collins, W.C.; Levitt, N.C.; Talbot, D.C.; Ganesan, T.S.; Harris, A.L. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. *Ann. Oncol.* **1999**, *10*, 923–927.

43. Holmes, W.F.; Soprano, D.R.; Soprano, K.J. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. *J. Biol. Chem.* **2002**, *277*, 45408–45419.

44. Loschen, G.; Flohe, L.; Chance, B. Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. *FEBS Lett.* **1971**, *18*, 261–264.

45. Rabilloud, T.; Heller, M.; Rigobello, M.P.; Bindoli, A.; Aebersold, R.; Lunardi, J. The mitochondrial antioxidant defence system and its response to oxidative stress. *Proteomics* **2001**, *1*, 1105–1110.

46. Banmeyer, I.; Marchand, C.; Clippe, A.; Knoops, B. Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. *FEBS Lett.* **2005**, *579*, 2327–2333.

47. Huh, J.Y.; Kim, Y.; Jeong, J.; Park, J.; Kim, I.; Huh, K.H.; Kim, Y.S.; Woo, H.A.; Rhee, S.G.; Lee, K.J.; Ha, H. Peroxiredoxin 3 Is a Key Molecule Regulating Adipocyte Oxidative Stress, Mitochondrial Biogenesis, and Adipokine Expression. *Antioxid. Redox Signal.* **2011**, In Press.
48. Nonn, L.; Williams, R.R.; Erickson, R.P.; Powis, G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. *Mol. Cell Biol.* **2003**, *23*, 916–922.

49. Lebovitz, R.M.; Zhang, H.; Vogel, H.; Cartwright, J., Jr.; Dionne, L.; Lu, N.; Huang, S.; Matzuk, M.M. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 9782–9787.

50. Hinerfeld, D.; Traini, M.D.; Weinberger, R.P.; Cochran, B.; Doctrow, S.R.; Harry, J.; Melov, S. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. *J. Neurochem.* **2004**, *88*, 657–667.

51. Ho, Y.S.; Magnenat, J.L.; Bronson, R.T.; Cao, J.; Gargano, M.; Sugawara, M.; Funk, C.D. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. *J. Biol. Chem.* **1997**, *272*, 16644–16651.

52. de Haan, J.B.; Bladier, C.; Griffiths, P.; Kelner, M.; O'Shea, R.D.; Cheung, N.S.; Bronson, R.T.; Silvestro, M.J.; Wild, S.; Zheng, S.S.; Beart, P.M.; Hertzog, P.J.; Kola, I. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide. *J. Biol. Chem.* **1998**, *273*, 22528–22536.

53. Crack, P.J.; Taylor, J.M.; Flentjar, N.J.; de Haan, J.; Hertzog, P.; Iannello, R.C.; Kola, I. Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. *J. Neurochem.* **2001**, *78*, 1389–1399.

54. Esworthy, R.S.; Ho, Y.S.; Chu, F.F. The Gpx1 gene encodes mitochondrial glutathione peroxidase in the mouse liver. *Arch. Biochem. Biophys.* **1997**, *340*, 59–63.

55. Panfili, E.; Sandri, G.; Ernster, L. Distribution of glutathione peroxidases and glutathione reductase in rat brain mitochondria. *FEBS Lett.* **1991**, *290*, 35–37.

56. Heerdt, B.G.; Houston, M.A.; Wilson, A.J.; Augenlicht, L.H. The intrinsic mitochondrial membrane potential (Deltapsim) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis. *Cancer Res.* **2003**, *63*, 6311–6319.

57. Cleveland, J.L.; Kastan, M.B. Cancer. A radical approach to treatment. *Nature* **2000**, *407*, 309–311.

58. Matei, D.; Schilder, J.; Sutton, G.; Perkins, S.; Breen, T.; Quon, C.; Sidor, C. Activity of 2-methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. *Gynecol. Oncol.* **2009**, *115*, 90–96.

59. Tevaarwerk, A.J.; Holen, K.D.; Alberti, D.B.; Sidor, C.; Arnott, J.; Quon, C.; Wilding, G.; Liu, G. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. *Clin. Cancer Res.* **2009**, *15*, 1460–1465.

60. Rajkumar, S.V.; Richardson, P.G.; Lacy, M.Q.; Dispenzieri, A.; Greipp, P.R.; Witzig, T.E.; Schlossman, R.; Sidor, C.F.; Anderson, K.C.; Gertz, M.A. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. *Clin. Cancer Res.* **2007**, *13*, 6162–6167.
61. Juarez, J.C.; Manuia, M.; Burnett, M.E.; Betancourt, O.; Boivin, B.; Shaw, D.E.; Tonks, N.K.; Mazar, A.P.; Donate, F. Superoxide dismutase 1 (SOD1) is essential for H$_2$O$_2$-mediated oxidation and inactivation of phosphatases in growth factor signaling. *Proc. Natl. Acad. Sci. USA* 2008, 105, 7147–7152.

62. Alexandre, J.; Nicco, C.; Chereau, C.; Laurent, A.; Weill, B.; Goldwasser, F.; Batteux, F. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. *J. Natl. Cancer. Inst.* 2006, 98, 236–244.

63. Maeda, H.; Hori, S.; Ohizumi, H.; Segawa, T.; Kakehi, Y.; Ogawa, O.; Kakizuka, A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine. *Cell Death Differ.* 2004, 11, 737–746.

64. Dragovich, T.; Gordon, M.; Mendelson, D.; Wong, L.; Modiano, M.; Chow, H.H.; Samulitis, B.; O'Day, S.; Grenier, K.; Hersh, E.; Dorr, R. Phase I trial of imexon in patients with advanced malignancy. *J. Clin. Oncol.* 2007, 25, 1779–1784.

65. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P.J.; Achanta, G.; Arlinghaus, R.B.; Liu, J.; Huang, P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. *Cancer Cell* 2006, 10, 241–252.

66. Xiao, D.; Lew, K.L.; Zeng, Y.; Xiao, H.; Marynowski, S.W.; Dhir, R.; Singh, S.V. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. *Carcinogenesis* 2006, 27, 2223–2234.

67. Brown, K.K.; Eriksson, S.E.; Arner, E.S.; Hampton, M.B. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. *Free Radic. Biol. Med.* 2008, 45, 494–502.

68. Huang, P.; Feng, L.; Oldham, E.A.; Keating, M.J.; Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. *Nature* 2000, 407, 390–395.

69. Wood, L.; Leese, M.R.; Leblond, B.; Woo, L.W.; Ganeshapillai, D.; Purohit, A.; Reed, M.J.; Potter, B.V.; Packham, G. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. *Anticancer Drug Des.* 2001, 16, 209–215.

70. Magda, D.; Miller, R.A. Motexafin gadolinium: a novel redox active drug for cancer therapy. *Semin. Cancer Biol.* 2006, 16, 466–476.

71. Bey, E.A.; Bentle, M.S.; Reinicke, K.E.; Dong, Y.; Yang, C.R.; Girard, L.; Minna, J.D.; Bornmann, W.G.; Gao, J.; Boothman, D.A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. *Proc. Natl. Acad. Sci. USA* 2007, 104, 11832–11837.

72. Tuma, R.S. Reactive oxygen species may have antitumor activity in metastatic melanoma. *J. Natl. Cancer Inst.* 2008, 100, 11–12.

73. Kirshner, J.R.; He, S.; Balasubramanyam, V.; Kepros, J.; Yang, C.Y.; Zhang, M.; Du, Z.; Barsoum, J.; Bertin, J. Elesclomol induces cancer cell apoptosis through oxidative stress. *Mol. Cancer Ther.* 2008, 7, 2319–2327.
74. Belzacq, A.S.; El Hamel, C.; Vieira, H.L.; Cohen, I.; Haouzi, D.; Metivier, D.; Marchetti, P.; Brenner, C.; Kroemer, G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001, 20, 7579–7587.

75. Guzman, M.L.; Rossi, R.M.; Neelakantan, S.; Li, X.; Corbett, C.A.; Hassane, D.C.; Becker, M.W.; Bennett, J.M.; Sullivan, E.; Lachowicz, J.L.; et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110, 4427–4435.

76. Guzman, M.L.; Rossi, R.M.; Karnischky, L.; Li, X.; Peterson, D.R.; Howard, D.S.; Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105, 4163–4169.

77. Chahboune, N.; Barrachina, I.; Royo, I.; Romero, V.; Saez, J.; Tormo, J.R.; De Pedro, N.; Estornell, E.; Zafra-Polo, M.C.; Pelaez, F.; Cortes, D. Guanaconetins, new antitumoral acetogenins, mitochondrial complex I and tumor cell growth inhibitors. Bioorg. Med. Chem. 2006, 14, 1089–1094.

78. Palmeira, C.M.; Wallace, K.B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol. 1997, 143, 338–347.

79. Petronilli, V.; Costantini, P.; Scorrano, L.; Colonna, R.; Passamonti, S.; Bernardi, P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 1994, 269, 16638–16642.

80. Wang, W.; Adachi, M.; Kawamura, R.; Sakamoto, H.; Hayashi, T.; Ishida, T.; Imai, K.; Shinomura, Y. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 2006, 11, 2225–2235.

81. Chae, H.Z.; Robison, K.; Poole, L.B.; Church, G.; Storz, G.; Rhee, S.G. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc. Natl. Acad. Sci. USA 1994, 91, 7017–7021.

82. Rhee, S.G.; Chae, H.Z.; Kim, K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 2005, 38, 1543–1552.

83. Choi, H.J.; Kang, S.W.; Yang, C.H.; Rhee, S.G.; Ryu, S.E. Crystal structure of a novel human peroxidase enzyme at 2.0 A resolution. Nat. Struct. Biol. 1998, 5, 400–406.

84. Kang, S.W.; Baines, I.C.; Rhee, S.G. Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. J. Biol. Chem. 1998, 273, 6303–6311.

85. Cerutti, P.A. Oxy-radicals and cancer. Lancet 1994, 344, 862–863.

86. Wood, Z.A.; Schroder, E.; Robin Harris, J.; Poole, L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28, 32–40.

87. Fujii, J.; Ikeda, Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep. 2002, 7, 123–130.
88. Kim, J.H.; Bogner, P.N.; Baek, S.H.; Ramnath, N.; Liang, P.; Kim, H.R.; Andrews, C.; Park, Y.M. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin. Cancer Res. 2008, 14, 2326–2333.

89. Chang, J.W.; Lee, S.H.; Jeong, J.Y.; Chae, H.Z.; Kim, Y.C.; Park, Z.Y.; Yoo, Y.J. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett. 2005, 579, 2873–2877.

90. Yanagawa, T.; Iwasa, S.; Ishii, T.; Tabuchi, K.; Yusa, H.; Onizawa, K.; Omura, K.; Harada, H.; Suzuki, H.; Yoshida, H. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000, 156, 27–35.

91. Song, I.S.; Kim, S.U.; Oh, N.S.; Kim, J.; Yu, D.Y.; Huang, S.M.; Kim, J.M.; Lee, D.S.; Kim, N.S. Peroxiredoxin I contributes to TRAIL resistance through suppression of redox-sensitive caspase activation in human hepatoma cells. Carcinogenesis 2009, 30, 1106–1114.

92. Karihtala, P.; Mantyniemi, A.; Kang, S.W.; Kinnula, V.L.; Soini, Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 2003, 9, 3418–3424.

93. Chung, Y.M.; Yoo, Y.D.; Park, J.K.; Kim, Y.T.; Kim, H.J. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 2001, 21, 1129–1133.

94. Zhang, P.; Liu, B.; Kang, S.W.; Seo, M.S.; Rhee, S.G.; Obeid, L.M. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bel-2. J. Biol. Chem. 1997, 272, 30615–30618.

95. Park, S.H.; Chung, Y.M.; Lee, Y.S.; Kim, H.J.; Kim, J.S.; Chae, H.Z.; Yoo, Y.D. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin. Cancer Res. 2000, 6, 4915–4920.

96. Yo, Y.D.; Chung, Y.M.; Park, J.K.; Ahn, C.M.; Kim, S.K.; Kim, H.J. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Exp. Mol. Med. 2002, 34, 273–277.

97. Lee, J.Y.; Jung, H.J.; Song, I.S.; Williams, M.S.; Choi, C.; Rhee, S.G.; Kim, J.; Kang, S.W. Protective role of cytosolic 2-cys peroxiredoxin in the TNF-alpha-induced apoptotic death of human cancer cells. Free Radic. Biol. Med. 2009, 47, 1162–1171.

98. Chen, M.F.; Chen, W.C.; Wu, C.T.; Lin, P.Y.; Shau, H.; Liao, S.K.; Yang, C.T.; Lee, K.D. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 1461–1472.

99. Chen, M.F.; Keng, P.C.; Shau, H.; Wu, C.T.; Hu, Y.C.; Liao, S.K.; Chen, W.C. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 581–591.

100. Park, S.Y.; Yu, X.; Ip, C.; Mohler, J.L.; Bogner, P.N.; Park, Y.M. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res. 2007, 67, 9294–9303.

101. Jang, J.S.; Cho, H.Y.; Lee, Y.J.; Ha, W.S.; Kim, H.W. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 2004, 14, 491–499.

102. Park, J.J.; Chang, H.W.; Jeong, E.J.; Roh, J.L.; Choi, S.H.; Jeon, S.Y.; Ko, G.H.; Kim, S.Y. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1196–1202.
103. Wei, Q.; Jiang, H.; Xiao, Z.; Baker, A.; Young, M.R.; Veenstra, T.D.; Colburn, N.H. Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. *Proc. Natl. Acad. Sci. USA* 2011, 108, 7004–7009.

104. Kinnula, V.L.; Lehtonen, S.; Kaarteenaho-Wiik, R.; Lakari, E.; Paakko, P.; Kang, S.W.; Rhee, S.G.; Soini, Y. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. *Thorax* 2002, 57, 157–164.

105. Wang, M.X.; Wei, A.; Yuan, J.; Trickett, A.; Knoops, B.; Murrell, G.A. Expression and regulation of peroxiredoxin 5 in human osteoarthritis. *FEBS Lett.* 2002, 531, 359–362.

106. Plaisant, F.; Clippe, A.; Vander Stricht, D.; Knoops, B.; Gressens, P. Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice. *Free Radic. Biol. Med.* 2003, 34, 862–872.

107. Zhou, Y.; Kok, K.H.; Chun, A.C.; Wong, C.M.; Wu, H.W.; Lin, M.C.; Fung, P.C.; Kung, H.; Jin, D.Y. Mouse peroxiredoxin V is a thoredoxin peroxidase that inhibits p53-induced apoptosis. *Biochem. Biophys. Res. Commun.* 2000, 268, 921–927.

108. Mikhailov, V.M.; Kropotov, A.V.; Zelenin, A.V.; Krutilina, R.I.; Kolesnikov, V.A.; Zelenina, I.A.; Baranov, A.N.; Shtein, G.I.; Ostapenko, O.V.; Tomilin, N.V.; Baranov, V.S. The BCL-xL and ACR-1 genes promote differentiation and reduce apoptosis in muscle fibers of mdx mice. *Genetika* 2002, 38, 1445–1450.

109. Yuan, J.; Murrell, G.A.; Trickett, A.; Landtmeters, M.; Knoops, B.; Wang, M.X. Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. *Biochim. Biophys. Acta.* 2004, 1693, 37–45.

110. Wang, X.; Phelan, S.A.; Petros, C.; Taylor, E.F.; Ledinsky, G.; Jurgens, G.; Forsman-Semb, K.; Paigen, B. Peroxiredoxin 6 deficiency and atherosclerosis susceptibility in mice: significance of genetic background for assessing atherosclerosis. *Atherosclerosis* 2004, 177, 61–70.

111. Strey, C.W.; Spellman, D.; Stieber, A.; Gonatas, J.O.; Wang, X.; Lambris, J.D.; Gonatas, N.K. Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. *Am. J. Pathol.* 2004, 165, 1701–1718.

112. Power, J.H.; Shannon, J.M.; Blumbergs, P.C.; Gai, W.P. Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson's disease and dementia with lewy bodies. *Am. J. Pathol.* 2002, 161, 885–894.

113. Krapfenbauer, K.; Yoo, B.C.; Fountoulakis, M.; Mitrova, E.; Lubec, G. Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease. *Electrophoresis* 2002, 23, 2541–2547.

114. Krapfenbauer, K.; Engidawork, E.; Cairns, N.; Fountoulakis, M.; Lubec, G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. *Brain Res.* 2003, 967, 152–160.

115. Munz, B.; Frank, S.; Hubner, G.; Olsen, E.; Werner, S. A novel type of glutathione peroxidase: expression and regulation during wound repair. *Biochem. J.* 1997, 326, 579–585.

116. Dierick, J.F.; Kalume, D.E.; Wenders, F.; Salmon, M.; Dieu, M.; Raes, M.; Ropstorff, P.; Toussaint, O. Identification of 30 protein species involved in replicative senescence and stress-induced premature senescence. *FEBS Lett.* 2002, 531, 499–504.
117. Lehtonen, S.T.; Svensk, A.M.; Soini, Y.; Paakko, P.; Hirvikoski, P.; Kang, S.W.; Saily, M.; Kinnula, V.L. Peroxiredoxins, a novel protein family in lung cancer. *Int. J. Cancer* 2004, 111, 514–521.

118. Hattori, F.; Murayama, N.; Noshita, T.; Oikawa, S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. *J. Neurochem.* 2003, 86, 860–868.

119. Chang, T.S.; Cho, C.S.; Park, S.; Yu, S.; Kang, S.W.; Rhee, S.G. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. *J. Biol. Chem.* 2004, 279, 41975–41984.

120. Kim, S.H.; Fountoulakis, M.; Cairns, N.; Lubec, G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. *J. Neural. Transm. Suppl.* 2001, 223–235.

121. Wonsey, D.R.; Zeller, K.I.; Dang, C.V. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. *Proc. Natl. Acad. Sci. USA* 2002, 99, 6649–6654.

122. Chae, H.Z.; Kim, H.J.; Kang, S.W.; Rhee, S.G. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. *Diabetes Res. Clin. Pract.* 1999, 45, 101–112.

123. Araki, M.; Nanri, H.; Ejima, K.; Murasato, Y.; Fujiwara, T.; Nakashima, Y.; Ikeda, M. Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. *J. Biol. Chem.* 1999, 274, 2271–2278.

124. Spyrou, G.; Enmark, E.; Miranda-Vizuete, A.; Gustafsson, J. Cloning and expression of a novel mammalian thioredoxin. *J. Biol. Chem.* 1997, 272, 2936–2941.

125. Lee, S.R.; Kim, J.R.; Kwon, K.S.; Yoon, H.W.; Levine, R.L.; Ginsburg, A.; Rhee, S.G. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. *J. Biol. Chem.* 1999, 274, 4722–4734.

126. Miranda-Vizuete, A.; Damdimopoulos, A.E.; Spyrou, G. The mitochondrial thioredoxin system. *Antioxid. Redox Signal.* 2000, 2, 801–810.

127. Pedrajas, J.R.; Miranda-Vizuete, A.; Javanmardy, N.; Gustafsson, J.A.; Spyrou, G. Mitochondria of Saccharomyces cerevisiae contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity. *J. Biol. Chem.* 2000, 275, 16296–16301.

128. Rabilloud, T.; Heller, M.; Gasnier, F.; Luche, S.; Rey, C.; Aebersold, R.; Benahmed, M.; Louisot, P.; Lunardi, J. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. *J. Biol. Chem.* 2002, 277, 19396–19401.

129. Woo, H.A.; Kang, S.W.; Kim, H.K.; Yang, K.S.; Chae, H.Z.; Rhee, S.G. Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfenic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence. *J. Biol. Chem.* 2003, 278, 47361–47364.

130. Saito, Y.; Nishio, K.; Ogawa, Y.; Kinumi, T.; Yoshida, Y.; Masuo, Y.; Niki, E. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. *Free Radic. Biol. Med.* 2007, 42, 675–685.
131. Noh, Y.H.; Baek, J.Y.; Jeong, W.; Rhee, S.G.; Chang, T.S. Sulfiredoxin Translocation into Mitochondria Plays a Crucial Role in Reducing Hyperoxidized Peroxiredoxin III. *J. Biol. Chem.* **2009**, *284*, 8470–8477.

132. Tanaka, T.; Hosoi, F.; Yamaguchi-Iwai, Y.; Nakamura, H.; Masutani, H.; Ueda, S.; Nishiyama, A.; Takeda, S.; Wada, H.; Spyrou, G.; Yodoi, J. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. *EMBO J.* **2002**, *21*, 1695–1703.

133. Nathanson, L.; Hall, T.C.; Schilling, A.; Miller, S. Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature. *Cancer Res.* **1969**, *29*, 419–425.

134. DeVita, V.T.; Schein, P.S. The use of drugs in combination for the treatment of cancer: rationale and results. *N. Engl. J. Med.* **1973**, *288*, 998–1006.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).